comprehensive -WSS

comprehensive

author：fashion 2025-10-01 00:49:13 - browse：56222

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： How state and local governments are sidelining science

WSS

Medicare’s new pay boost for primary care is angering specialists

How state and local governments are sidelining science

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Secretariat’s lessons for human medicine

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

A new drug could help frostbite victims avoid its ravages

Wikipedia

comprehensive

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Ventyx halts psoriasis drug development after lackluster trial results

Continuity nursing helped my family in our darkest PICU moments

WATCH: Why do our ears pop?

Supreme Court strikes down use of affirmative action

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Medical records are filled with copy

Medicare Advantage enrollment hits roughly 33.4 million

Guidelines to prevent youth baseball injuries need more muscle

Measles policy set amid Florida outbreak alarms vaccine proponents

hotspot

WATCH: Why do our ears pop?

Ventyx halts psoriasis drug development after lackluster trial results

MD Anderson's Padmanee Sharma responds to research credit suit

Abridge raises $150m as clinical notes automation market heats up

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

NIH chief: government has fallen behind pharma on clinical trials

focus

leisure time

leisure time

Wikipedia